EUVIMEDEUVIMED entdecken
Crossref

Biotransformation and disposition characteristics of HSK7653 , a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes

Yi-Cong Bian iD, Jian Meng, Tao Hu, Sheng Ma, Chen-Rong Huang, Feng-Yi Zhang, Qing-He Wu, Hua Zhang, Xiao-Yan Chen, Li-Yan Miao

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Yi-Cong Bian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Haisco Pharmaceutical Group Co., Ltd., The National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou Health Leading Talent.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the metabolism and disposition characteristics of HSK7653 in healthy male Chinese participants.

Methods

A single oral dose of 80 μCi (25 mg) [ 14 C]HSK7653 capsules was administered to six healthy participants, and blood, plasma, urine and faeces were collected. Quantitative and qualitative analysis was conducted to investigate the pharmacokinetics, blood‐to‐plasma ratio, mass balance and metabolism of HSK7653.

Results

The drug was well absorbed and reached a maximum concentration at 1.25 h. The drug‐related components (HSK7653 and its metabolites) were eliminated slowly, with a half‐life (t 1/2 ) of 111 h. Unchanged HSK7653 contributed to more than 97% of the total radioactivity in all plasma samples. The blood‐to‐plasma ratio (0.573‐0.845) indicated that HSK7653 did not tend to distribute into blood cells. At 504 h postdose, up to 95.9% of the dose was excreted, including 79.8% in urine and 16.1% in faeces. Most of the radioactivity (75.5% dose) in excreta was unchanged HSK7653. In addition, nine metabolites were detected in urine and faeces. The most abundant metabolite was M6‐2, a dioxidation product of HSK7653, which accounted for 4.73% and 2.63% of the dose in urine and faeces, respectively. The main metabolic pathways of HSK7653 in vivo included oxidation, pyrrole ring opening and sulphonamide hydrolysation.

Conclusion

HSK7653 was well absorbed, slightly metabolized and slowly excreted in humans. The high plasma exposure and long t 1/2 of HSK7653 may contribute to its long‐lasting efficacy as a long‐acting dipeptidyl peptidase‐4 inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2HumansMaleAdultBiotransformationHalf-LifeFecesYoung AdultHealthy VolunteersHypoglycemic AgentsAdministration, Oral

Stichwörter der Autor:innen

HSK7653long‐acting dipeptidyl peptidase‐4 inhibitormass balancemetabolismpharmacokineticsradiolabelled

Substanzen

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute for Interdisciplinary Drug Research and Translational Sciences, Soochow University, Suzhou, China.
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Haisco Pharmaceutical Group Company Ltd., Chengdu, China.
  • National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Yi-Cong Bian

Förderung

  • Haisco Pharmaceutical Group Co., Ltd.
  • The National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University
  • Suzhou Health Leading Talent
  • Key R&D Program of Jiangsu Province
  • The Priority Academic Program Development of the Jiangsu Higher Education Institutes

Zitieren

APA

Bian, Y. C., Meng, J., Hu, T., Ma, S., Huang, C. R., Zhang, F. Y., Wu, Q. H., Zhang, H., Chen, X. Y., & Miao, L. Y. (2024). Biotransformation and disposition characteristics of HSK7653 , a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15605

Vancouver

Bian YC, Meng J, Hu T, Ma S, Huang CR, Zhang FY, et al. Biotransformation and disposition characteristics of HSK7653 , a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15605

BibTeX
@article{Bian2024,
  author = {Bian, Yi-Cong and Meng, Jian and Hu, Tao and Ma, Sheng and Huang, Chen-Rong and Zhang, Feng-Yi and Wu, Qing-He and Zhang, Hua and Chen, Xiao-Yan and Miao, Li-Yan},
  title = {Biotransformation and disposition characteristics of HSK7653 , a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15605}
}
Kostenlos starten →